TMCnet News
Affimed Announces Pricing of Public Offering of Common StockAffimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the pricing of its previously announced public offering of 10,000,000 of its common shares at a public offering price of $1.80 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be approximately $16.9 million. The offering is expected to close on or about January 25, 2017, subject to customary closing conditions. BMO Capital Markets Corp. and Wells Fargo Securities, LLC are acting as joint book-running managers, and Trout Capital LLC is acting as co-manager. A shelf registration statement relating to these securities filed with the Securities and Exchange Commission (SEC) was declared effective by the SEC on October 23, 2015. The offering will be made only by means of a prospectus and prospectus supplement. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available at the SEC's website located at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus related to the offering may be obtained, when available, by contacting BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 1036, Attention: Equity Syndicate Department, or by telephone at (800) 414-3627, or by email at [email protected], or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by email at [email protected], or by telephone at (800) 326-5897. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Affimed N.V. Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. AFFIMED FORWARD-LOOKING STATEMENTS Affimed IR Contact: Caroline Stewart, Head IR Affimed Media Contact: Anca Alexandru, Head of Communications, EU IR |